The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for
cycloplegic refractions in pediatric populations. This will be a prospective double-blinded
randomized clinical trial (RCT), multi center, with randomized sequencing of cycloplegic
agent; each patient received one agent at one visit, and the other agent in the next visit (2
different visits ≥ 1 week apart) within 3 months.